Search
Immuneering Corp
IMRXAdd to Watchlist
5.190USD
+0.140+2.77%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
335.74MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.77%
5 Days
+9.03%
1 Month
+15.85%
6 Months
-21.60%
Year to Date
-21.12%
1 Year
+50.43%
Key Figures
5.070Open
5.250High
1.16MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.80%Turnover Ratio
5.050Prev. Close
5.010Low
3.99MTurnover
LossP/E Static
1.63P/B
0.00%Div Yield TTM
-41.01%ROA
10.08052wk High
0.71Volume Ratio
-61.04MNet Profit
64.69MShares
-1.0576EPS TTM
0.34Beta
-43.84%ROE
1.58052wk Low
4.75%Amplitude
-1507.91%Gross Margin
335.74MMarket Cap
2.15Reward/Risk
5.91%Risk Rate
TradingKey Stock Score of Immuneering Corp
Currency: USD Updated: 2026-07-02Key Insights
Immuneering Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 104 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.00.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Immuneering Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Immuneering Corp Highlights
StrengthsRisks
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Undervalued
The company’s latest PE is -4.91, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 30.53M shares, increasing 3.63% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
17.000
Target Price
+236.63%
Upside Space
Immuneering Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Immuneering Corp Info
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Ticker SymbolIMRX
CompanyImmuneering Corp
CEOZeskind (Benjamin J)
Websitehttps://immuneering.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Immuneering Corp (IMRX)?
The current price of Immuneering Corp (IMRX) is 5.19.
What is the symbol of Immuneering Corp?
The ticker symbol of Immuneering Corp is IMRX.
What is the 52-week high of Immuneering Corp?
The 52-week high of Immuneering Corp is 10.08.
What is the 52-week low of Immuneering Corp?
The 52-week low of Immuneering Corp is 1.58.
What is the market capitalization of Immuneering Corp?
The market capitalization of Immuneering Corp is 335.74M.
Is Immuneering Corp (IMRX) currently rated as Buy, Hold, or Sell?
According to analysts, Immuneering Corp (IMRX) has an overall rating of Buy, with a price target of 17.00.
What is the Earnings Per Share (EPS TTM) of Immuneering Corp (IMRX)?
The Earnings Per Share (EPS TTM) of Immuneering Corp (IMRX) is -1.27.